German OTC Market Is Europe's Largest

21 March 1997

Germany's over-the-counter drug market, at around $3.9 billion, isEurope's largest, says a new study from Datamonitor, available through the Marketletter. Germany also has had a large semi-ethical sector, but this has shrunk with the introduction of negative lists and will disappear altogether once proposed new legislation takes effect.

Over 20% of Germany's total drug market, which was worth more than $16.5 billion in 1995, is accounted for by pure OTC products. This is the highest proportion for OTCs in any European market.

The biggest OTC categories are cold/flu remedies and analgesics, while vitamins and minerals, gastrointestinals and dermatologicals are also big sellers. Most OTC categories, including the two leading groups, may only be sold in pharmacies, which account for 89% of total OTC sales. Only products such as vitamin and mineral supplements, tonics and herbal treatments may be sold in drug stores and other retail outlets, and even some of these are pharmacy-only. Drugstores represent only 7% of OTC sales.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight